Attovia Reports Positive 12-Week Phase 1b Results for ATTO-1310
The company said a single dose delivered itch relief and skin lesion improvements through Week 12 in patients with chronic pruritus and high-itch atopic dermatitis.
Story updates
09:09:40 PM UTC
SquawkNews
Attovia reported that 82% of ATTO-1310-treated chronic pruritus patients achieved PP-NRS4 at Week 12 versus 22% with placebo (p < 0.01). The company plans to start two Phase 2 trials in 1H 2027.Material DetailsContext by AI AnalystThese are early clinical results extending the previously reported W…